# Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

> **NCT04143594** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 183 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Oral Lenacapavir
- **DRUG:** F/TAF
- **DRUG:** Subcutaneous Lenacapavir
- **DRUG:** TAF
- **DRUG:** BIC
- **DRUG:** B/F/TAF

## Key facts

- **NCT ID:** NCT04143594
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-22
- **Primary completion:** 2021-10-05
- **Final completion:** 2023-09-19
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2024-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04143594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04143594, "Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04143594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*